// App-Quantinova.ai

2651 : Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma

Researchers

Presenter

  • Jeffrey Wallin

Principal Investigators

  • Genevive Hernandez

  • Mahesh Yadav

  • Suchit Jhunjhunwala

  • Lelia Delamarre

  • Xian He

  • John Powderly

  • Christopher Lieu

  • S Gail Eckhardt

  • Herbert Hurwitz

  • Howard S. Hochster

  • Janet Murphy

  • Vincent Leveque

  • Edward Cha

  • Roel Funke

  • Daniel Waterkamp

  • Priti Hegde

  • Johanna Bendell

Medical Centers

  • Genentech, Inc., South San Francisico, CA

  • Lombardi Comprehensive Cancer Center, Washington, DC

  • Carolina BioOncology Institute, Huntersville, NC

  • University of Colorado Anschutz Medical Campus, Aurora, CO

  • Duke University Medical Center, Durham, NC

  • Yale Cancer Center, New Haven, CT

  • Massachusetts General Hospital, Boston, MA

  • Sarah Cannon Research Institute, Nashville, TN

Locations

  • United States

Companies

  • Genentech, Inc.

  • Carolina BioOnocolog

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

  • Granzyme B

  • Vascular endothelial growth factor A

Drug/Treatment

  • Atezolizumab

  • Bevacizumab

  • Oxaliplatin, 5-fluorouracil and folic acid

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved